Substituted propionyl derivatives
CA 2275603 A1 · Owner: Daiichi Pharmaceutical Co. Ltd. · Inventors: Kagechika, Katsuji; Nagashima, Hajime; Usui, Hiroyuki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds represented by general formula (1) or salts thereof; and drugs containing the same as the active ingredient. Because of having potent squalene synthetase inhibitory effects these compounds are useful as remedies or preventives for hypercholesterolemia etc. In said formula, X1 represents , esterifiable carboxy etc.; Y1 represents a single bond, etc.; at least one of A1, A2 and A3 represents: -R2-a1-R3-a2 wherein R2 represents a divalent , hydrocarbon group; R3 represents a single bond etc.; a1 and a2 represent each a single bond, -S-, etc.; and represents the bond to Q1 Q2 or Q3; while the , remainder(s) represent: -R8-a3-R9-a4 wherein R8 and R9 represent each a , single bond …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 26, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 26, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 26, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.